Related Experiment Video

Updated: Jul 3, 2026

Deciphering the Molecular Mechanism and Function of Pore-Forming Toxins Using Leishmania major
08:17

Deciphering the Molecular Mechanism and Function of Pore-Forming Toxins Using Leishmania major

Published on: October 28, 2022

Pentoxifylline down modulate in vitro T cell responses and attenuate pathology in Leishmania and HTLV-I infections

Amelia Ribeiro de Jesus1, Tânia Luna, Roque Pacheco de Almeida

  • 1Serviço de Imunologia, Hospital Universitário Prof. Edgard Santos, Universidade Federal da Bahia, Salvador, BA, Brazil.

International Immunopharmacology
|August 9, 2008
PubMed

Insights

Pentoxifylline inhibits tumor necrosis factor-alpha (TNF-alpha) production, a key factor in inflammatory diseases like HTLV-1 myelopathy and leishmaniasis. Clinical studies show pentoxifylline

Area of Science:

  • Immunology
  • Molecular Biology
  • Infectious Diseases

Background:

  • Tumor necrosis factor-alpha (TNF-alpha) is a cytokine implicated in tissue damage in chronic inflammatory, autoimmune, and infectious diseases.
  • HTLV-1 associated myelopathy and leishmaniasis are inflammatory conditions where TNF-alpha plays a pathogenic role.

Purpose of the Study:

  • To review evidence supporting TNF-alpha's role in HTLV-1 associated myelopathy and leishmaniasis pathogenesis.
  • To examine the effects of pentoxifylline on TNF-alpha production in vitro and in vivo.
  • To summarize clinical trial results of pentoxifylline for treating these diseases.

Main Methods:

  • Review of studies on TNF-alpha's involvement in disease pathogenesis.
  • In vitro experiments demonstrating pentoxifylline's inhibition of TNF-alpha and IFN-gamma in PBMC from HTLV-1 patients.
  • In vivo assessment of pentoxifylline's effect on serum TNF-alpha in leishmaniasis patients.
  • Analysis of clinical studies from the past decade on pentoxifylline treatment outcomes.

Main Results:

  • Evidence supports TNF-alpha's role in the pathogenesis of HTLV-1 associated myelopathy and leishmaniasis.
  • Pentoxifylline demonstrated in vitro inhibition of spontaneous TNF-alpha and IFN-gamma production in PBMC from HTLV-1 patients.
  • Pentoxifylline showed in vivo inhibition of TNF-alpha in sera from mucosal leishmaniasis patients.
  • Clinical studies indicate potential benefits of pentoxifylline in treating these conditions.

Conclusions:

  • TNF-alpha is a significant factor in the pathology of HTLV-1 associated myelopathy and leishmaniasis.
  • Pentoxifylline effectively suppresses TNF-alpha production through phosphodiesterase IV inhibition.
  • Clinical evidence suggests pentoxifylline is a promising therapeutic agent for HTLV-1 associated myelopathy and leishmaniasis.

Related Concept Videos

Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Leishmaniasis01:30

Leishmaniasis

Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms: